1977 - Foundation
The company was founded in 1977 and began conducting research on medicinal plants, specifically African Voacanga, which normally have pharmacological activity.
1986 - Award
Medal for merit in research and development.
1991 - Entry into USSR
An important moment was when COVEX entered the Soviet Union in 1991, thanks to the patent that had been granted a few years earlier in that part of the world, when the company had only 20 employees.
This patent led to a $9,000,000 contract with the USSR Department of Health for the sale of Vinpocetine tablets (Vinpocetine Covex 5 mg), a drug for neurological use.
1998 - Award
Silver Award at the Hall of Inventions in Geneva, Switzerland
2000 - Factory expansion
Start of works to expand the factory. Investment of €6 million.
2004 - Award
2004 Reemprende Award “Project with the greatest international projection”.
2005 - Award
SME 2005 Internationalisation Award.
2014 - China Pioneer Pharma
On 1 July 2014 China Pioneer Pharma Holdings Ltd. acquired Covex S.A. Since then Covex has been part of a group listed on the Hong Kong Stock Exchange.
Pioneer Pharma is one of the largest providers of integrated marketing, promotion and channel management services dedicated to imported pharmaceuticals and healthcare products in China.
Founded in 1996, Pioneer has been growing rapidly. Today it has established an impressive service network covering more than 20,000 hospitals and other medical institutions in 31 provinces, municipalities and autonomous regions in China.
Its business headquarters are located in Shanghai, the financial centre of China, and its logistics centre is in Hubei Province, one of the best connected and centrally located areas in the country.
It is a young, dynamic company, embracing both traditional Chinese values and Western business culture and practice. Its partners choose it for its solid track record, impressive service network, diligent attention and quality of service.
2018 - Expansion of facilities
Start of works to expand the factory with a new pharmaceutical plant. Investment of €5 million.
